Lisata Therapeutics, Inc. (NASDAQ:LSTA) Short Interest Up 29.6% in February

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was the target of a significant increase in short interest in February. As of February 15th, there was short interest totalling 26,700 shares, an increase of 29.6% from the January 31st total of 20,600 shares. Based on an average daily volume of 42,200 shares, the days-to-cover ratio is currently 0.6 days. Currently, 0.4% of the company’s shares are short sold.

Institutional Investors Weigh In On Lisata Therapeutics

A hedge fund recently bought a new stake in Lisata Therapeutics stock. Citadel Advisors LLC bought a new stake in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 23,273 shares of the company’s stock, valued at approximately $69,000. Citadel Advisors LLC owned about 0.28% of Lisata Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 8.94% of the company’s stock.

Lisata Therapeutics Stock Performance

Shares of NASDAQ LSTA remained flat at $2.15 during midday trading on Tuesday. The stock had a trading volume of 6,376 shares, compared to its average volume of 55,131. The company has a market capitalization of $18.05 million, a P/E ratio of -0.86 and a beta of 1.14. Lisata Therapeutics has a 52-week low of $2.14 and a 52-week high of $4.20. The company’s 50 day moving average is $2.92 and its 200 day moving average is $2.90.

Lisata Therapeutics (NASDAQ:LSTA) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.21. The firm had revenue of $1.00 million for the quarter. Research analysts predict that Lisata Therapeutics will post -2.66 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Lisata Therapeutics in a report on Wednesday, December 11th.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.